FDA Approves FIDAXOMICIN — ORIG Submission by HIKMA, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows HIKMA as the sponsor of FIDAXOMICIN, with the generic name recorded as unspecified and dosage form TABLET. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. This specific application is submission type ORIG (submission number 1) under application number ANDA219737, with a submission status date of 20261007. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Frequently asked questions

What review priority did FDA assign?

FDA designated this submission as: STANDARD.

What dosage form is FIDAXOMICIN?

FIDAXOMICIN is formulated as: TABLET.

What did FDA approve?

FDA's record shows anda approval for FIDAXOMICIN (unspecified), dosage form TABLET, sponsored by HIKMA, under application number ANDA219737. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards.

Related enforcement actions

• Approval: HIKMA — ANDA approval: DEFLAZACORT (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: SOLRIAMFETOL (unspecified) →
• Approval (recent): RUBICON RESEARCH — ANDA approval: HYDROCHLOROTHIAZIDE (unspecified) →
• Approval (recent): CREEKWOOD PHARMS — ANDA approval: MIRABEGRON (unspecified) →
• Approval (recent): ASTRAZENECA AB — NDA approval: BREZTRI AEROSPHERE (unspecified) →
• Approval (recent): TEVA NEUROSCIENCE INC — NDA approval: WELTRUZA (unspecified) →
• Approval (recent): GENENTECH INC — BLA approval: TECENTRIQ (unspecified) →
• Approval (recent): ANNORA PHARMA PRIVATE LIMITED — ANDA approval: PITOLISANT (unspecified) →